RecruitingPhase 1NCT06522581

Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy


Sponsor

Armed Forces Hospital, Pakistan

Enrollment

200 participants

Start Date

Jan 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births. Infants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.


Eligibility

Min Age: 1 DayMax Age: 30 Days

Inclusion Criteria2

  • all indoor newborn babies with HIE II and III
  • who have not received therapeutic hypothermia

Exclusion Criteria4

  • grade I HIE
  • Babies on TH
  • babies whose parents do not give consent for inclusion in study
  • babies with major congential malformations -

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCiticoline Sodium

one group of neonates with confirmed HIE grade II and III will receive injection citicoline through IV route within 06 hours of birth


Locations(1)

MH

Rawalpindi, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06522581


Related Trials